Migraine Drugs Market Size to grow by USD 1.34 billion between 2024-2028
The Migraine Drugs Market is segmented by End-user (Hospitals, Retail, and Online), Type (Preventive and Abortive), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 1.34 billion, at a CAGR of 6.36% during the forecast period. There are several companies that are contributing to the market as per this report. Rising advances in migraine drugs .
By End-user, the Hospitals segment is projected to dominate the market size in 2024
The global migraine drugs market's hospitals segment is experiencing robust growth, driven by the rising prevalence and diagnosis of migraine, as well as the expansion of public and private specialty healthcare facilities. Major hospitals and clinics, characterized by advanced medical infrastructure, are significant consumers of high-quality medical products and consumables in bulk. Notable advancements in migraine treatment, such as the FDA's April 2023 approval of QULIPTA (atogepant) for preventive migraine treatment in adults, are anticipated to fuel market expansion during the forecast period.
For insights on company offerings- Request a sample report!
By Type, Preventive segment is expected to hold the largest market size for the year 2024
In the global migraine drugs market, the preventive segment is experiencing robust growth due to its ability to decrease attack frequency and severity. This segment employs both off-label and generic medications, such as beta-blockers like propranolol and atenolol. Regular intake of preventive drugs enhances the efficacy of symptom-relieving medicines during migraine episodes. Notably, beta-blockers, antiepileptics like topiramate and divalproex, and CGRP blockers or receptor antagonists are utilized for migraine prevention.
Why is North America forecasted to hold the largest regional market size in 2024?
In the North American market for migraine drugs, robust growth is attributed to a sophisticated healthcare infrastructure delivering top-tier migraine treatments via clinics and hospitals. Healthcare spending escalations in nations like the US and Canada further fuel market expansion. Key players, including Amgen, Eli Lilly and Company, and Novartis, dominate the North American landscape, with strategic alliances bolstering the commercialization of migraine therapeutics. The region's market is fortified by an increasing number of FDA-approved medications for migraine treatment.
To access the valuable insights - Download the Free Sample Report
Research Analysis Overview
The Migraine Drugs Market encompasses a range of therapeutics designed to alleviate the symptoms and manifestations of migraine, a neurological condition characterized by sensory disturbances, including vomiting, nausea, and loss of appetite. Migraines can also present with olfactory, auditory, and visual disturbances, such as phonophobia, photophobia, and osmophobia. Migraines are often associated with vascular diseases, cardiac diseases, and pulmonary diseases. The younger generation, with their sedentary lifestyles and increased patient awareness, is driving the demand for effective migraine treatments. The Migraine Drugs Market includes anticonvulsant drugs, antipsychotics, analgesics, and pain-relieving medications. These therapeutics work by targeting the nervous system, specifically the olfactory groove and the bloodstream, to mitigate the symptoms of migraines. Migraines can also manifest as neurological medical diseases, such as migraine with aura, migraine without aura, and status migrainosus. Effective management of these conditions requires a comprehensive approach, including lifestyle modifications and pharmacological interventions. In conclusion, the Migraine Drugs Market offers a diverse range of therapeutics to address the complex and multifaceted nature of migraines. These drugs aim to provide relief from the debilitating symptoms of migraines, improving the quality of life for those affected.
Market Research Overview
In the realm of the global healthcare industry, the pharmaceuticals market serves as a significant sector, encompassing entities involved in R&D and manufacturing of various drug classes, including migraine drugs. Technavio's market analysis calculates the healthcare industry's size based on the consolidated revenue generated by pharmaceutical manufacturers and providers. The pharmaceuticals market expansion is primarily driven by demographic trends, such as the increasing global population aging above 60 years. - The Migraine Drugs Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
